



Subject: Imogam<sup>®</sup> Rabies–HT (Rabies Immune Globulin (Human) USP, Heat Treated) Discontinuation

Dear Customer,

Sanofi has decided to discontinue the production of Imogam<sup>®</sup> Rabies–HT (Rabies Immune Globulin (Human) USP, Heat Treated) and its human origin anti-rabies immunoglobulins (HRIGs). We expect to continue to be able to supply doses through December 2022 based on supply capacity and associated demand.

The discontinuation of Imogam<sup>®</sup> Rabies - HT is not linked to safety or quality issues. This decision was taken after conducting a thorough evaluation of possible alternatives.

We regret any potential impact this decision may have to our customers and their patients. Please refer to the following CDC website for currently US licensed HRIGs:

- <https://www.cdc.gov/rabies/resources/availability.html>

Sanofi continues focusing expertise & assets on our core business, which is the development of vaccines for the prevention of infectious diseases. We thank you for your continued immunization efforts and ongoing partnership with Sanofi.

Imogam Rabies-HT, in conjunction with the standard series of Rabies Vaccine vaccinations, is indicated for passive immunization of individuals suspected of exposure to rabies with one exception: persons who have completed one of the recommended regimens with a cell culture or other rabies vaccine.

### **IMPORTANT SAFETY INFORMATION**

Imogam Rabies-HT should not be given in repeated doses once vaccine treatment has begun.

Imogam Rabies-HT is made from human plasma. Therefore, it may carry a risk of transmitting infectious agents. Per the FDA, under the current screening and testing protocol the transmission of infectious agents has not occurred.

Persons with IgA deficiency have increased potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products containing IgA. Local adverse reactions to the Imogam Rabies-HT include tenderness, pain, and soreness or stiffness of the muscles at the injection site. Mild systemic adverse reactions to the globulin after intramuscular injection are uncommon but may occur. Imogam Rabies-HT should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immune globulin.

### **IMPORTANT SAFETY INFORMATION CONTINUED ON NEXT PAGE**



**IMPORTANT SAFETY INFORMATION CONTINUED**

Do not administer intravenously. Never administer Rabies-HT in the same syringe or into the same anatomical site as the rabies vaccine dose.

Treatment with Imogam Rabies-HT may not protect all individuals

**Please see the full accompanying [Prescribing Information](#) for Imogam<sup>®</sup> Rabies-HT.**

If you have any questions, please do not hesitate to reach out to your Sanofi representative or call 1-800-VACCINE (1-800-822-2463).

Sincerely,

A handwritten signature in black ink that reads "Stacy Kearney Bucha".

Stacy Kearney Bucha

Head of the US Meninge, Travel & Endemics Franchise

MAT-US-2203228-v1.0-04/2022